Biomarkers Market
Biomarkers Market by Offering (Consumables, Software, Service), Type (Safety, Efficacy, Validation), Research Area (Genomics, Proteomics), Technology (PCR, NGS, MS), Disease (Cancer, CVD), Application (Diagnostic, Drug Discovery) - Global Forecast to 2031
BIOMARKERS MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, at a CAGR of 10.5% during the forecast period. The market was valued at USD 62.67 billion in 2025. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Current Market Size (2026): USD 67.95 Billion
Projected Market Size (2031): USD 112.10 Billion
CAGR (2026–2031): 10.5% -
SEGMENT LEADERSHIP:
Fastest-Growing Region: Asia Pacific is projected to register the highest CAGR of 12.4% during the forecast period.
Offering Leader: Consumables segment held the largest share of 73.4% in 2025.
Type Leader: Safety biomarkers segment dominated the global biomarkers market with a share of 48.5% in 2025.
Research Area Leader: Genomics segment is expected to dominate the market during the forecast period. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
F. Hoffmann-La Roche (Switzerland), Abbott (US), and Thermo Fisher Scientific (US) were identified as the star players in the global biomarkers market, given their strong market share and product footprint.
DNAnexus, Inc. (US), Biocartis NV (Belgium), and Alamar Biosciences, Inc. (US) have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The global biomarkers market is expanding rapidly, driven by the surge in precision-medicine programs and the routine use of biomarker-guided tests in oncology, cardiology, and other complex diseases.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The biomarkers market is experiencing rapid growth due to changes in manufacturing and regulatory environments that align with precision medicine and biologic therapies. The increasing demand for diagnoses in cancer, cardiovascular diseases, and neurological conditions is driving the adoption of high-performance assay kits, multiplexing platforms, and single-sample multi-omics solutions that deliver accurate and clinically relevant data. Hospitals, laboratory networks, and contract development and manufacturing organizations (CDMOs) are embracing validated, automation-friendly biomarker consumables and solutions that yield fast results, support companion diagnostics, and comply with strict FDA regulations.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rising adoption of precision medicine and companion diagnostics

-
Growing use of NGS, PCR, proteomics, and multi-omics platforms
Level
-
High cost of advanced biomarker discovery and validation
-
Complex regulatory and reimbursement pathways
Level
-
Co-development of biomarkers with targeted therapies and immunotherapies
-
Expansion of blood-based biomarkers for oncology and neurology
Level
-
Translating discovery biomarkers into clinically validated tests
-
Patient heterogeneity and disease complexity
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rising adoption of precision medicine and companion diagnostics
The rising adoption of precision medicine and companion diagnostics is driving the demand for biomarker discovery and validation solutions. Advances in genomics, proteomics, metabolomics, and high-throughput screening technologies are improving the efficiency of biomarker identification, enhancing clinical validation capabilities, and supporting greater scalability in both research and clinical applications.
Restraint: High cost of advanced biomarker discovery and validation
The high costs associated with advanced analytical platforms, multi-omics technologies, clinical validation studies, and regulatory compliance continue to hinder the widespread adoption of biomarkers. Significant investments are needed in infrastructure, skilled expertise, and data integration capabilities, which present challenges, especially for smaller research organizations and emerging biotechnology companies.
Opportunity: Co-development of biomarkers with targeted therapies and immunotherapies
The increasing integration of biomarkers with targeted therapies and immunotherapies is creating opportunities for the collaborative development of drugs and diagnostics. There is a growing emphasis on patient stratification, treatment response prediction, and personalized treatment approaches. This focus is driving demand for companion diagnostic solutions and expanding their commercial potential in precision healthcare.
Challenges: Translating discovery biomarkers into clinically validated tests
Transforming biomarker discoveries from the research stage into clinically validated diagnostic tests is challenging for several reasons. These include complex validation requirements, regulatory expectations, concerns about reproducibility, and a lack of standardization across clinical settings. To achieve successful commercialization and adoption of these tests, it is essential to ensure analytical accuracy and demonstrate clinical utility.
BIOMARKERS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
NGS-based comprehensive genomic profiling (CGP) and multi-omic biomarkers (including high-sensitive Troponin T, NT-proBNP) for cancer, cardiovascular, and neurology applications. | Supports personalized treatment plans, rapid rule-in/rule-out diagnostics from single tests, earlier detection, and companion diagnostics across oncology, cardiology, and neurology. |
|
|
High-sensitivity immunoassays and blood-based biomarkers for cancer, cardiovascular, and neurological diseases, including amyloid β testing for Alzheimer’s. | Enables non-invasive early diagnosis, risk stratification, and monitoring for chronic conditions like Alzheimer's, cancer, and CVD. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The biomarkers market is a complex ecosystem that includes assay developers, suppliers of kits and instruments, clinical laboratories, hospitals, and biopharmaceutical companies. Biomarker vendors provide validated assays and analytical platforms that pharmaceutical companies, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs) incorporate into clinical trial designs, patient stratification, and therapeutic response assessments. Hospitals and reference laboratories then integrate these biomarker solutions into clinical practice, with support from healthcare IT vendors, distribution channels, and reimbursement systems that facilitate test adoption, optimize supply chains, and ensure reimbursement. This highly interconnected value chain enables the global implementation of biomarker-based precision medicine strategies within healthcare systems.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Global Biomarkers Market, by Offering
In 2025, consumables accounted for the largest share of the biomarkers market, driven by the steady, high-volume demand for assay kits, reagents, plates, and cartridges in routine clinical diagnostics and extensive research programs.
Global Biomarkers Market, by Type
In 2025, safety biomarkers accounted for the largest share, fueled by their expanding role in real-time tracking of organ toxicity and adverse drug effects across clinical trials and post-approval monitoring.
Global Biomarkers Market, by Research Area
In 2025, genomics will be a leading research area due to the widespread adoption of next-generation sequencing and gene panels to identify treatment-relevant mutations and develop integrated biomarker profiles for oncology and rare disease initiatives.
Global Biomarkers Market, by Technology
In 2025, immunoassay technologies held the largest market share due to their automation-friendly nature and suitability for high-volume routine testing in hospitals and reference laboratories.
Global Biomarkers Market, by Disease Indication
In 2025, cancer dominated biomarker spending, as oncology programs rely heavily on molecular and protein markers for early detection, patient stratification, minimal residual disease tracking, and therapy monitoring.
Global Biomarkers Market, by Application
Clinical diagnostics accounted for the largest share of the biomarkers market, as hospitals and reference labs increasingly use biomarker-based tests for routine cancer, cardiovascular, and infectious disease workups.
Global Biomarkers Market, by End User
Pharmaceutical & biotechnology companies formed the largest end-user group by harnessing biomarkers to mitigate R&D risks, design efficient clinical trials, and secure regulatory approval for companion diagnostics tied to novel therapies.
REGION
APAC to be fastest-growing region in market during forecast period
During the forecast period, the Asia Pacific region is expected to experience the fastest growth in the global biomarkers market. This growth is attributed to the expansion of healthcare infrastructure, increased clinical trial activity, and robust government support for precision medicine initiatives, particularly in key countries such as China, India, and Japan.

BIOMARKERS MARKET: COMPANY EVALUATION MATRIX
In the global biomarkers market, F. Hoffmann-La Roche Ltd. (Switzerland) is the star player, offering an extensive portfolio of FDA-cleared and CE-marked assays, automated immunoassay platforms, and integrated diagnostic solutions trusted worldwide for high-throughput testing in oncology, cardiology, neurology, and infectious disease panels. Guardant Health (emerging leader) leverages advanced NGS liquid biopsy tests, comprehensive cancer panels, and AI-driven analytics to transform circulating tumor DNA biomarkers into actionable insights for early detection, therapy selection, and minimal residual disease monitoring across major healthcare systems globally.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Merck KGaA (Germany)
- Thermo Fisher Scientific Inc. (US)
- Abbott (US)
- QIAGEN (Netherlands)
- Agilent Technologies, Inc. (US)
- Revvity (US)
- Charles River Laboratories (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 62.47 Billion |
| Market Forecast in 2026 (Value) | USD 67.95 Billion |
| Market Forecast in 2031 (Value) | USD 112.10 Billion |
| Growth Rate | CAGR of 10.5% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends |
| Segments Covered |
|
| Countries Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
WHAT IS IN IT FOR YOU: BIOMARKERS MARKET REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Regulatory compliance for global markets | Assessed regulatory requirements for biomarker assays across major markets, including FDA, EMA, and PMDA guidelines. | Reduces time-to-market risk by ensuring assays meet local regulations and compliance standards. |
| Emerging biomarker trends and unmet needs | Identified high-value biomarkers in oncology, immunology, and chronic diseases with limited commercial availability. | Informs pipeline prioritization, partnership opportunities, and innovation roadmaps. |
RECENT DEVELOPMENTS
- June 2026 : Roche's first companion diagnostic to assess PTEN protein in prostate cancer has been approved by the FDA. The VENTANA PTEN assay allows for the identification of patients, leading to more targeted treatment decisions.
- January 2025 : Thermo Fisher Scientific, Inc. has partnered with the UK Biobank Pharma Proteomics Project (UKB-PPP) to support the largest biomarker-focused proteomics study in the world.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global biomarkers market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives at major market players, and industry consultants, to gather and validate critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the global biomarkers market. The secondary sources used for this study include the American Society of Clinical Oncology (ASCO), Association for Molecular Pathology (AMP), Canadian Alliance for Healthy Hearts and Minds (CAHHM), Canadian Institute for Health Information (CIHI), Central Drugs Standard Control Organisation (CDSCO), Center for Disease Evaluation and Research (CDER), Clinical Laboratory Standards Institute (CLSI), Centers for Disease Control and Prevention (CDC), Clinicaltrials.gov, European Medicines Agency (EMA), Food and Drug Administration (FDA), GLOBOCAN, International Agency for Research on Cancer (IARC), Ministry of Food and Drug Safety (MFDS), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), National Comprehensive Cancer Network (NCCN), National Medical Products Administration (NMPA), Organisation for Economic Co-operation and Development (OECD), Personalized Medicine Coalition (PMC), Population Health Research Institute (PHRI), Pharmaceuticals and Medical Devices Agency (PMDA), World Bank, World Health Organization (WHO), corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations, among others. These sources were also used to obtain key information on major players, market classification and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
Following an initial assessment of the global biomarkers market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were conducted with key supply-side participants, including C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% were conducted with demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephone discussions to comprehensively understand market dynamics.
The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both bottom-up and top-down approaches were used to estimate and validate the total size of the global biomarkers market. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:
- A list of the major global players operating in the biomarkers market was generated.
- The revenues generated from their biomarker products have been determined through annual reports and secondary sources (including paid databases)
- The products were mapped according to the segments of the market. Percentage shares and splits were determined by each segment's revenue. This was verified using secondary sources and by industry experts.
- All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.
Biomarkers Market : Top-Down and Bottom-Up Approach

Data Triangulation
After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
A biomarker is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response. Biomarkers can be molecular, histologic, radiographic, or physiological characteristics that provide valuable insights into normal and pathological processes.
The biomarkers market encompasses a broad range of products and services that support biomarker discovery, validation, and application in clinical and research settings. This includes offerings such as consumables (assay kits, reagents, and instruments), software tools, and related services that facilitate biomarker analysis. The market report analyzes biomarker usage across multiple applications, including clinical diagnostics, drug discovery & development, personalized medicine, and clinical research. It also examines the adoption of biomarkers across key research areas, including oncology, neurology, cardiology, infectious diseases, and metabolic disorders. Furthermore, the report segments the market by type into safety, efficacy, and validation biomarkers. The study also considers regional trends, end-user adoption, and technological advancements shaping the global biomarkers landscape.
Key Stakeholders
- Academic & Research Institutes
- Biomarkers Assay & Reagent Manufacturers, Vendors, and Distributors
- Start-ups, platform technology & service providers
- Contract Research Organizations (CROs)
- Diagnostic product providing companies
- Market Research and Consulting Firms
- Pharmaceutical and Biotechnology Companies
- Regulatory Agencies
- Venture Capitalists
- Forensic Labs
- Government organizations
- Private Research Firms
- Contract Development and Manufacturing Organizations (CDMOs)
- Hospitals and Diagnostic Laboratories
Report Objectives
- To define, describe, and forecast the global biomarkers market by offering, type, research area, technology, disease indication, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biomarkers market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global biomarkers market and comprehensively analyze their product & service portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the biomarkers market
- To benchmark players within the biomarkers market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product & service strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations to meet the company’s needs. The following customization options are available for this report:
Portfolio Assesment
- Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies.
Regional Analysis
- A further breakdown of the Rest of Asia Pacific biomarkers market into countries
- A further breakdown of the Rest of Europe biomarkers market into countries
- A further breakdown of the Rest of Latin America biomarkers market into countries
Company Information
- Detailed analysis and profiling of additional market players (up to three).
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Biomarkers Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
- Canada Biomarkers Market
- US Biomarkers Market
- Germany Biomarkers Market
- UK Biomarkers Market
- France Biomarkers Market
- Italy Biomarkers Market
- Spain Biomarkers Market
- China Biomarkers Market
- Japan Biomarkers Market
- India Biomarkers Market
- South Korea Biomarkers Market
- Australia Biomarkers Market
- Brazil Biomarkers Market
- Mexico Biomarkers Market
- Saudi Arabia Biomarkers Market
- UAE Biomarkers Market
Growth opportunities and latent adjacency in Biomarkers Market
Jasper
Jun, 2026
I reviewed the Biomarkers Market report to evaluate segmentation across diagnostic and prognostic applications, and it clarified how strongly clinical validation is shaping commercial adoption decisions..
Rowan
Jun, 2026
After going through the Biomarkers Market insights, I see clearer investment signals around companion diagnostics and liquid biopsy platforms, especially where recurring revenue models are emerging..
Elowen
Jun, 2026
From an operational standpoint, the Biomarkers Market analysis helped me understand how variability in assay standardization and regulatory pathways is impacting lab integration timelines..
Patrick
Mar, 2022
Looking forward to gain more insights on the global Biomarkers Market.
Raymond
Mar, 2022
What are the growth opportunities in Biomarkers Market?.
Jack
Mar, 2022
Can you enlighten us on the end users in Biomarkers Market?.